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HydroCoils Are Associated with Lower Angiographic
Recurrence Rates Than Are Bare Platinum Coils in Treatment of
“Difficult-to-Treat” Aneurysms: A Post Hoc Subgroup Analysis
of the HELPS Trial
W. Brinjikji, P.M. White, H. Nahser, J. Wardlaw, R. Sellar, A. Gholkar, H.J. Cloft, and D.F. Kallmes
ABSTRACT
BACKGROUND AND PURPOSE: The HydroCoil Endovascular Aneurysm Occlusion and Packing Study was a randomized controlled trial
that compared HydroCoils to bare platinum coils. Using data from this trial, we performed a subgroup analysis of angiographic and clinical
outcomes of patients with “difficult-to-treat” aneurysms, defined as irregularly shaped and/or having a dome-to-neck ratio of1.5.
MATERIALS AND METHODS: Separate subgroup analyses comparing outcomes of treatment with HydroCoils to that of bare platinum
coils were performed for the following: 1) irregularly shaped aneurysms, 2) regularly shaped aneurysms, 3) aneurysms with a dome-to-neck
ratio of1.5, and 4) aneurysms with a dome-to-neck ratio of1.5. For each subgroup analysis, the following outcomes were studied at the
last follow-up (3–18 months): 1) any recurrence, 2) major recurrence, 3) re-treatment, and 4) an mRS score of 2. Multivariate logistic
regression analysis was performed to determine if the HydroCoil was independently associated with improved outcomes in these
subgroups.
RESULTS: Among the patients with an irregularly shaped aneurysm, the HydroCoil was associated with lower major recurrence rates than
the bare platinum coils (17 of 66 [26%] vs 30 of 69 [44%], respectively; P  .046). Among the patients with an aneurysm with a small
dome-to-neck ratio, the HydroCoil was associated with lower major recurrence rates than the bare platinum coils (18 of 73 [24.7%] vs 32 of
76 [42.1%], respectively; P  .02). No difference in major recurrence was seen between HydroCoils and bare platinum coils for regularly
shaped aneurysms (42 of 152 [27.6%] vs 52 of 162 [32.1%], respectively; P .39) or aneurysmswith a large dome-to-neck ratio (41 of 145 [28.3%]
vs 50 of 155 [32.3%], respectively; P .53).
CONCLUSIONS: This unplanned post hoc subgroup analysis found that HydroCoils are associatedwith improved angiographic outcomes
in the treatment of irregularly shaped aneurysms and aneurysms with a dome-to-neck ratio of1.5. Because this was a post hoc analysis,
these results are not reliable and absolutely should not alter clinical practice but, rather, may inform the design of future randomized
controlled trials.
ABBREVIATIONS: D/N dome-to-neck ratio; HELPS HydroCoil Endovascular Aneurysm Occlusion and Packing Study
The HydroCoil Endovascular Aneurysm Occlusion and Pack-ing Study (HELPS) was a randomized controlled trial that
compared the rate of clinical and angiographic outcomes in pa-
tients treated with the HydroCoil Embolic System (MicroVen-
tion, Tustin, California) and those treated with bare platinum
coils.1 This study found a statistically significant lower rate of
major recurrence among aneurysms treated with the HydroCoil
(a secondary trial outcome) but found no difference in the rates of
trial primary composite outcome, which was a composite mea-
sure of adverse outcomes includingmajor aneurysm recurrence at
18 months after treatment and procedure-related deaths and
morbidity that resulted in the patients not having follow-up
angiography.
Hydrogel coils are manufactured with an expansile hydrogel
that has been shown to result in improved aneurysm filling when
compared with bare platinum coils.2 Experimental models have
suggested that hydrogel-coated coils are more effective in filling
areas of potential aneurysm growth, such as aneurysm rupture
points, lobulations, and daughter sacs, and along the aneurysm
neck.3-5 Aneurysms with a small dome-to-neck ratio (D/N)
(1.5) and lobulated/irregularly shaped aneurysms have been
identified as difficult to coil and at high risk of recanalization after
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coil embolization with bare platinum coils.6 On the basis of find-
ings from experimentalmodels, we hypothesized thatHydroCoils
would result in a significantly lower rate of aneurysm recurrence
than would bare platinum coils in “difficult-to-treat” aneurysms,
defined as irregularly shaped aneurysms and aneurysms with a
D/N of1.5.We evaluated this hypothesis by using data from the
HELPS trial and performing the following subgroup analyses:
1) analysis of angiographic and clinical outcomes in treatment
groups of patients with an irregularly or regularly shaped an-
eurysm treated with the HydroCoil versus those treated with a
bare platinum coil and 2) analysis of angiographic and clinical
outcomes of patients with a small D/N (1.5) aneurysm or
large D/N (1.5) aneurysm treated with the HydroCoil versus
those treated with a bare platinum coil. Because this was not a
prespecified subgroup analysis, it is important to mention that
the results of this study should not be used to alter clinical




The HELPS trial enrolled patients from 24 centers in 7 countries.
Enrolled were patients 1) with a previously untreated intracranial
aneurysm of 2–25 mm in maximum diameter, 2) aged 18–75
years, 3) determined by a neurovascular team to benefit from
coiling, 4) who were not pregnant, 5) who had anatomy such that
endovascular occlusion was deemed possible, 6) who had not
been previously enrolled in another trial, and 7) whom the neu-
rointerventionist performing the surgerywas content orwilling to
randomly assign to bare platinum or HydroCoil Embolic System
coils. Patients who had more than one aneurysm that required
treatment in one procedure were excluded. Details regarding in-
formed consent, ethics approval, the coiling procedures, random-
ization techniques, baseline demographics, and data handling are
shown elsewhere.1,7
For the purposes of this analysis, we identified the following
subgroups of patients: 1) patients with an irregularly shaped an-
eurysm, 2) patients with a regularly shaped aneurysm, 3) patients
with an aneurysm with a small D/N (1.5), and 4) patients with
an aneurysm with a large D/N (1.5). Analysis of outcomes in
these subgroups was not prespecified in the design of the HELPS
trial. An aneurysm was considered irregularly shaped if it was
multilobulated (ie, bilobed or multilobular). These features were
recorded at the time of randomization, and trial arms were
matched on them as part of the minimization algorithm (also
minimized on aneurysm size, rupture status intention to use a coil
assist device, and randomized in the United States versus any-
where else in the world).7
Outcomes
For each subgroup of patients, the following baseline and proce-
dural characteristics were obtained: sex, age, D/N, rupture status,
use of assist device, aneurysm shape, and baseline World Federa-
tion of Neurosurgical Societies score. For the purposes of this
subgroup analysis, we studied the following individual outcomes:
1) any recurrence, 2) major recurrence, 3) modified Rankin Scale
of2, and 4) re-treatment. The presence of aneurysm recurrence
was defined as increased contrast filling of an aneurysm by using a
revised 3-point Montreal scale (complete, near-complete, or in-
complete occlusion). A major recurrence was defined as a recur-
rence sufficiently large enough to technically allow placement of
further coils as defined by the core laboratory blind assessment of
angiograms.8 Re-treatmentwas classified as any further treatment
of the target aneurysm. The mRS assessment was performed by a
postal questionnaire completed by each patient or by his or her
main caretaker and was independent of the interventional team.
The outcomes listed above were studied at the last clinical or an-
giographic follow-up. For each subgroup, we compared the rate
of these outcomes between patients randomly assigned to theHy-
droCoil group and those randomly assigned to the bare platinum
group.
Statistical Analysis
All means are presented with their corresponding standard devi-
ations. Comparisons between groups of these categoric outcomes
were performed by using the Fisher exact test or ANOVA. Multi-
variate logistic regression analyses were performed to determine if
differences between theHydroCoil and control groups existed for
the following outcomes: 1) any recurrence at last follow-up, 2)
major recurrence at last follow-up, 3) an mRS score of2 at last
follow-up, and 4) re-treatment at last follow-up. Multivariate lo-
gistic regression analyses were performed to determine if coil type
was independently associated with any of the outcomes listed
above for each subgroup. When performing subgroup analysis
according to aneurysm shape, we adjusted for aneurysm size,
D/N, rupture status, and use of an assist device.When performing
the subgroup analysis according to aneurysm D/N, we adjusted
for aneurysm size, shape, rupture status, and use of an assist de-
vice. Statistical analysis was performed by using JMP 10.0 Pro
(www.jmp.com; SAS Institute, Cary, North Carolina).
Role of Funding Source
The study sponsor (MicroVention) had no part in trial design,
data collection, analysis, or reporting, which were organized by
the steering committee. The corresponding author had full access
to all the data and had final responsibility for the decision to
submit for publication.
RESULTS
Patient and Aneurysm Characteristics
Details of baseline patient characteristics for all patients and an-
eurysms treated in the HELPS trial were described previously.1
One hundred fifty-three aneurysms (30.7%) were irregular in
shape, and 346 aneurysms (69.3%) were regular in shape. When
comparing patient characteristics according to aneurysm shape,
there was no difference in the proportion of aneurysms in each
group that had recently ruptured; 56.9% of the irregularly shaped
aneurysms (87 of 153) and 51.6% of the regularly shaped aneu-
rysms (179 of 346) had recently ruptured (P .29). There was a
higher proportion of small aneurysms in the irregularly shaped
aneurysm group (36.6% [56 of 153]) than in the regularly shaped
aneurysm group (20.8% [72 of 346]) and, correspondingly, a
higher proportion of large aneurysms in the regularly shaped an-
eurysm group (19.3% [67 of 346]) than in the irregularly shaped
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aneurysm group (10.5% [16 of 153]) (P  .0003). However, the
overall mean maximum aneurysm dimension was higher in the ir-
regularly shaped aneurysm group than in the regularly shaped aneu-
rysm group (8.9  3.7 vs 7.5  3.2 mm, respectively; P  .0001).
These data are summarized in Table 1.
One hundred sixty-four aneurysms had a D/N of 1.5
(32.9%), and 335 aneurysms (67.1%) had a D/N of 1.5. The
proportions of recently ruptured aneurysms were similar in the
small D/N group (51.2% [84 of 164]) and the large D/N group
(54.2% [182 of 335]; P .57). As expected, patients in the small
D/N groupweremore likely to have had an assist device used than
those in the large D/N group (55.6% [90 of 164] vs 40.4% [133 of
335], respectively; P .002). The distributions of aneurysm sizes
were similar between groups (P .05); however, the overall mean
aneurysm size was lower in the small D/N group than in the large
D/N group (7.2  3.1 vs 8.2  3.5 mm, respectively; P  .001).
These data are summarized in Table 2.
Univariate Outcomes According to Aneurysm Shape
For irregularly shaped aneurysms, HydroCoil treatment was as-
sociated with significantly lower rates of any angiographic recur-
rence than treatment with a bare platinum coil (34.9% [23 of 66]
vs 59.4% [41 of 69], respectively; P  .004) and a significantly
lower rate of major recurrence (25.8% [17 of 66] vs 43.5% [30 of
69], respectively; P  .046). There was no difference in re-treat-
ment rates between the HydroCoil and bare platinum groups
(2.6% [2 of 76] vs 3.9% [3 of 77], respectively; P .66). The rates
of good neurologic outcome were similar in the HydroCoil and
bare platinum groups (90.0% [63 of 70] vs 86.3% [63 of 73],
respectively; P .61).
For regularly shaped aneurysms, there was no difference in the
rates of any recurrence between theHydroCoil and bare platinum
groups (43.0% [65 of 151] vs 46.3% [75 of 162], respectively; P
.57) or in the rates of major recurrence (27.6% [42 of 152] vs
32.1% [52 of 162], respectively; P .39). There was no difference
in re-treatment rates between the HydroCoil and bare platinum
groups (2.3% [4 of 173] vs 4.6% [8 of 173], respectively; P .26).
The rates of good neurologic outcome were similar in the Hydro-
Coil and bare platinum groups (87.0% [141 of 162] vs 89.0% [146
of 164], respectively; P  .58). These data are summarized in
Table 3.
Univariate Outcomes According to Aneurysm Dome-to-
Neck Ratio
For aneurysms with a small D/N, HydroCoil treatment was asso-
ciated with significantly lower rates of any angiographic recur-
rence than treatment with a bare platinum coil (35.6% [26 of 73]
vs 55.3% [42 of 76], respectively;P .02) and a significantly lower
rate of major recurrence (24.7% [18 of 73] vs 42.1% [32 of 76],
respectively; P  .02). There was no difference in re-treatment
rates between the HydroCoil and bare platinum groups (1.2% [1
of 83] vs 3.7% [3 of 81], respectively; P .36). The rates of good
neurologic outcome were similar in the HydroCoil and bare plat-
inum groups (88.3% [68 of 77] vs 89.7% [70 of 78], respectively;
P .80).
For aneurysms with a large D/N, there was no difference in the
rates of any recurrence between theHydroCoil and bare platinum
groups (43.1% [62 of 144] vs 47.7% [74 of 155], respectively; P
.49) or the rates of major recurrence (28.3% [41 of 145] vs 32.3%







No. (%) 153 (30.7) 346 (69.3)
Mean (SD) age, y 52.3 (11.8) 52.1 (11.6) .86
Female, no. (%) 108 (70.6) 243 (70.0) .92
Recently ruptured, no. (%) 87 (56.9) 179 (51.6) .29
Assist device used, no. (%) 79 (52.3) 144 (42.4) .05
Small D/N ratio, no. (%) 43 (28.1) 121 (34.9) .15
Aneurysm size, no. (%)
Small 56 (36.6) 72 (20.8) .0003
Medium 81 (52.9) 208 (59.9)
Large 16 (10.5) 67 (19.3)
Mean (SD) size, mm 8.9 (3.7) 7.5 (3.2) .0001
WFNS score, no. (%)
0 62 (40.5) 156 (45.0) .38
I 73 (47.7) 161 (46.4)
II 16 (10.5) 26 (7.5)
III 1(0.7 4 (1.2)
VI 1 (0.7) 0 (0.0)
Note:—D/N indicates dome-to-neck ratio; WFNS, World Federation of Neurosur-
gical Societies.
Table 2: Characteristics of patients with a small D/N aneurysm




Total patients, no. (%) 164 (32.9) 335 (67.1)
Mean (SD) age, y 52.5 (11.4) 51.9 (11.7) .64
Female, no. (%) 118 (72.0) 233 (69.4) .6
Recently ruptured, no. (%) 84 (51.2) 182 (54.2) .57
Assist device used, no. (%) 90 (55.6) 133 (40.4) .002
Irregular shape, no. (%) 121 (73.8) 226 (67.3) .15
Aneurysm size, no. (%)
Small 36 (22.0) 47 (14.0) .05
Medium 93 (56.7) 196 (58.3)
Large 35 (21.3) 93 (27.7)
Mean (SD) size, mm 7.2 (3.1) 8.2 (3.5) .001
WFNS, no. (%)
0 76 (46.3) 142 (42.3) .51
I 71 (43.3) 163 (48.5)
II 14 (8.5) 28 (8.3)
III 3 (1.8) 2 (0.6)
VI 0 (0.0) 1 (0.3)
Table 3: Univariate outcomes according to aneurysm shape
Outcome
Irregularly Shaped Regularly Shaped
HydroCoil, n/N (%) Bare Platinum, n/N (%) P HydroCoil, n/N (%) Bare Platinum, n/N (%) P
Good neurologic outcome 63/70 (90.0) 63/73 (86.3) .61 141/162 (87.0) 146/164 (89.0) .58
Any recurrence 23/66 (34.9) 41/69 (59.4) .004 65/151 (43.0) 75/162 (46.3) .57
Major recurrence 17/66 (25.8) 30/69 (43.5) .046 42/152 (27.6) 52/162 (32.1) .39
Re-treatment 2/76 (2.6) 3/77 (3.9) .66 4/173 (2.3) 8/173 (4.6) .26
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[50 of 155], respectively; P  .53). There was no difference in
re-treatment rates between the HydroCoil and bare platinum
groups (3.0% [5 of 166] vs 4.7% [8 of 169], respectively; P .57).
The rates of good neurologic outcome were similar in the Hydro-
Coil and bare platinum groups (87.7% [136 of 155] vs 87.4% [139
of 159], respectively; P  1.00). These data are summarized in
Table 4.
Multivariate Analysis
Whenwe adjusted for aneurysm size, D/N, rupture status, and use
of an assist device in the irregularly shaped aneurysm subgroup,
use of the HydroCoil was associated with decreased odds of any
recurrence (OR, 0.34 [95% CI, 0.19–0.89]; P  .003) and de-
creased odds of major recurrence (OR, 0.42 [95%CI, 0.19–0.89];
P .02). There was no difference in the odds of good neurologic
outcome (OR, 1.56 [95%CI, 0.55–4.69]; P .40) or re-treatment
(OR, 0.57 [95% CI, 0.07–3.76]; P .56).
In the regularly shaped aneurysm subgroup, HydroCoils were
not associated with any improvement in the odds of any recur-
rence (OR, 0.87 [95% CI, 0.54–1.39]; P .55), major recurrence
(OR, 0.79 [95% CI, 0.47–1.32]; P  .36), good neurologic out-
come (OR, 0.81 [95% CI, 0.41–1.59]; P  .54), or re-treatment
(OR, 0.45 [95% CI, 0.11–1.49]; P  .19) when we compared
HydroCoils with bare platinum coils. These data are summarized
in Table 3.
When we adjusted for aneurysm size and shape, rupture sta-
tus, and use of an assist device in the small D/N aneurysm sub-
group, the use of HydroCoils was associated with decreased odds
of any recurrence (OR, 0.44 [95% CI, 0.22–0.87]; P  .02) and
major recurrence (OR, 0.42 [95% CI, 0.19–0.89]; P .02) in the
treatment of aneurysms with a small D/N. There was no differ-
ence in good neurologic outcomes (OR, 0.81 [95% CI, 0.29–
2.28]; P .69) or re-treatment rates (OR, 0.26 [95% CI, 0.01–
2.16]; P  .22).
For the large D/N aneurysm subgroup, HydroCoils were not
associated with any significant improvement in the odds of any
recurrence (OR, 0.78 [95%CI, 0.48–1.26]; P .32), major recur-
rence (OR, 0.79 [95% CI, 0.47–1.33]; P  .38), good neurologic
outcome (OR, 1.04 [95%CI, 0.53–2.06];P .91), or re-treatment
(OR, 0.61 [95% CI, 0.18–1.87]; P .38). These data are summa-
rized in Table 4.
DISCUSSION
In this unplanned post hoc subgroup analysis of patients in the
HELPS trial, we found that embolization with the HydroCoil,
compared with a bare platinum coil, was associated with signifi-
cantly lower rates of any recurrence and major recurrence in an-
eurysms with a small D/N and irregularly shaped aneurysms. This
improvement was seen on the univariate analysis and when we
adjusted for confounding variables such as aneurysm size, use of
adjunctive devices, and aneurysm rupture status, all of which are
independently associated with propensity for aneurysm recur-
rence. No difference was seen between HydroCoils and bare plat-
inum coils in the treatment of aneurysms with a large D/N and
regularly shaped aneurysms. These findings are important, be-
cause patients with irregularly shaped aneurysms and aneurysms
with a small D/N are generally at a higher risk of recurrence; thus,
identifying safe and effective endovascular treatments for such
aneurysms is of utmost importance.
A number of previous studies have found that aneurysms with
a small D/N and irregularly shaped aneurysms are more difficult
to treat and at higher risk of recurrence after endovascular coiling
with bare platinum coils than aneurysms with a large D/N and
regularly shaped aneurysms, respectively.6,9-12 This analysis on
the HELPS control arm confirms these as risk factors for recur-
rence. Aneurysms with a small D/N are prone to have neck rem-
nants after coiling, which can result in recanalization of the aneu-
rysm, because they are exposed to high wall shear stress and
blood-flow velocities.13,14 Irregular aneurysm geometries also
present a challenge in endovascular coiling. Aneurysms with
daughter sacs or multilobular configurations are prone to higher
rates of growth and rupture.15,16 Because of this tendency, achiev-
ing high packing attenuations in such aneurysms may be impor-
tant for sufficiently reducing intra-aneurysmal blood-flow veloc-
ity and wall shear stress to prevent further growth of such weak
points within the aneurysm.17
There are a number of potential reasons whyHydroCoils were
independently associated with reduced recurrence rates in the
treatment of wide-neck and irregularly shaped aneurysms. As
mentioned previously, irregularly shaped aneurysms with multi-
lobular configurations or daughter sacs have been shown to be
more likely to grow and rupture. Because HydroCoils are de-
signed with an expansile hydrogel that fills more of the aneurys-
mal lumen than platinum coils, they provide higher rates of an-
eurysm packing.18,19 By expanding and achieving higher packing
attenuations, HydroCoils may allow for increased conformation to
geometric irregularities of intracranial aneurysms, such as aneurysm
rupture points.3 The expansile property of these coils likely explains
why the recurrence rates for aneurysmswitha smallD/Ntreatedwith
HydroCoils were lower than for those treated with bare platinum
coils. Histologic studies in humans and rabbits have shown that
HydroCoils are more effective at sealing the aneurysm neck.4,20
Killer et al21 found that HydroCoils resulted in higher rates of
angiographic and histologic occlusion at both the aneurysm neck
and the dome, which increased over time.
Bare platinum and modified coils have been compared in a
number of studies. One meta-analysis of 82 studies found no dif-
Table 4: Univariate outcomes according to aneurysm D/N
Outcome
Small D/N Large D/N
HydroCoil, n/N (%) Bare Platinum, n/N (%) P HydroCoil, n/N (%) Bare Platinum, n/N (%) P
Good neurologic outcome 68/77 (88.3) 70/78 (89.7) .80 136/155 (87.7) 139/159 (87.4) 1.00
Any recurrence 26/73 (35.6) 42/76 (55.3) .02 62/144 (43.1) 74/155 (47.7) .49
Major recurrence 18/73 (24.7) 32/76 (42.1) .02 41/145 (28.3) 50/155 (32.3) .53
Re-treatment 1/83 (1.2) 3/81 (3.7) .36 5/166 (3.0) 8/169 (4.7) .57
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ference in angiographic outcomes between bare platinum coils,
HydroCoils, and Cerecyte coils (Codman Neurovascular, Rayn-
ham,Massachusetts).22However, no subgroup analyses were per-
formed to examine the relative benefits of modified coils in easily
identified difficult-to-treat subgroups, such aswide-neck or irreg-
ularly shaped aneurysms. Single-center studies have found that,
when compared with bare platinum coils, HydroCoils are associ-
ated with decreased recurrence rates; however, none was a ran-
domized controlled trial, and many were too small for subgroup
analyses to define which patients may benefit most from Hydro-
Coil treatment.23,24 The HELPS trial found 8.6% fewer major
angiographic recurrences for HydroCoil- versus bare platinum–
treated aneurysms (P .049).1 Clinical trials for other modified
coils, such as the Matrix (Stryker, Kalamazoo, Michigan) and
Cerecyte coils, failed to show any significant benefit for polygly-
colic acid/polyglycolic/polylactic acid–modified versus bare plat-
inum coils.11,25 Our data suggest that hydrogel-modified coils are
more beneficial in certain subsets of patients and aneurysms; re-
currence rates were reduced 17%–18% in patients with an aneu-
rysm with a small D/N or an irregularly shaped aneurysm.
Our study had several limitations. First, because this was not a
prespecified subgroup analysis for the HELPS trial, these data
should not necessarily alter clinical practice but, rather, serve as a
guide for the design of future trials comparingmodified with bare
platinum coils in reducing aneurysm recurrence rates. No fol-
low-updata on aneurysm recurrence and re-treatmentwere avail-
able beyond 18 months. Given this significantly higher rate of
major recurrence in the small D/N and irregularly shaped aneu-
rysm control groups, it is conceivable that more of these patients
would go on to re-treatment during the long-term follow-up pe-
riod. However, this suggestion is purely speculative. The combi-
nation of low power and lack of consistent follow-up beyond 18
monthsmay have contributed to the lack of statistical significance
in aneurysm re-treatment rates between the groups, despite the
higher rates of major recurrence in the control group. Another
limitation is the fact that there is wide interobserver and intraob-
server variability in assessments of aneurysm geometric irregular-
ities such as dome-to-neck ratio, lobularity, and the presence of
daughter sacs.26 The core laboratory in this study assessed angio-
graphic recurrence but did not assess aneurysm morphology.
Last, we did not study differences in packing attenuation between
groups.
CONCLUSIONS
Our subgroup analysis of the HELPS trial found that treatment of
irregularly shaped and relatively wide-neck aneurysms with Hy-
droCoils was associated with significantly lower major andminor
recurrence rates than treatment with bare platinum coils during
the study period. Because this was not a prespecified analysis,
these results are not reliable enough to alter clinical practice and
should in no way alter the way in which these patients with an
irregularly shaped aneurysm or an aneurysm with a small dome-
to-neck ratio are treated. Rather, these results should guide the
development and design of future randomized controlled trials
on the use of modified coils in the treatment of intracranial aneu-
rysms, because these findings suggest that inclusion of such diffi-
cult-to-treat aneurysms in future clinical trials may help to dem-
onstrate the benefits that modified coils have compared to
conventional bare platinum coils.
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